Literature DB >> 24145643

GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors.

Markku Miettinen1, Peter A McCue, Maarit Sarlomo-Rikala, Janusz Rys, Piotr Czapiewski, Krzysztof Wazny, Renata Langfort, Piotr Waloszczyk, Wojciech Biernat, Jerzy Lasota, Zengfeng Wang.   

Abstract

GATA3 is a transcription factor important in the differentiation of breast epithelia, urothelia, and subsets of T lymphocytes. It has been suggested to be useful in the evaluation of carcinomas of mammary or urothelial origin or metastatic carcinomas, but its distribution in normal and neoplastic tissues is incompletely mapped. In this study, we examined normal developing and adult tissues and 2040 epithelial and 460 mesenchymal or neuroectodermal neoplasms for GATA3 expression to explore its diagnostic value in surgical pathology, using monoclonal antibody (clone L50-823) and Leica Bond automated immunohistochemistry. GATA3 was expressed in trophoblast, fetal and adult epidermis, adult mammary and some salivary gland and sweat gland ductal epithelia, urothelia, distal nephron in developing and adult tissues, some prostatic basal cells, and subsets of T lymphocytes. It was expressed stronger in fetal than in adult mesothelia and was absent in respiratory and gastrointestinal epithelia. In epithelial neoplasms, GATA3 was expressed in >90% of primary and metastatic ductal and lobular carcinomas of the breast, urothelial, and cutaneous basal cell carcinomas and trophoblastic and endodermal sinus tumors. In metastatic breast carcinomas, it was more sensitive than GCDFP. Among squamous cell carcinomas, the expression was highest in the skin (81%) and lower in cervical (33%), laryngeal (16%), and pulmonary tumors (12%). Common positivity was found in skin adnexal tumors (100%), mesothelioma (58%), salivary gland (43%), and pancreatic (37%) ductal carcinomas, whereas frequency of expression in adenocarcinomas of lung, stomach, colon, endometrium, ovary, and prostate was <10%. Chromophobe renal cell carcinoma was a unique renal tumor with frequent positivity (51%), whereas oncocytomas were positive in 17% of cases but other types only rarely. Among mesenchymal and neuroectodermal tumors, paragangliomas were usually positive, which sets these tumors apart from epithelial neuroendocrine tumors. Mesenchymal tumors were only sporadically positive, except epithelia of biphasic synovial sarcomas. GATA3 is a useful marker in the characterization of not only mammary and urothelial but also renal and germ cell tumors, mesotheliomas, and paragangliomas. The multiple specificities of GATA3 should be taken into account when using this marker to detect metastatic mammary or urothelial carcinomas.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24145643      PMCID: PMC3991431          DOI: 10.1097/PAS.0b013e3182a0218f

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  29 in total

Review 1.  An updated view on transcription factor GATA3-mediated regulation of Th1 and Th2 cell differentiation.

Authors:  Ryoji Yagi; Jinfang Zhu; William E Paul
Journal:  Int Immunol       Date:  2011-06-01       Impact factor: 4.823

2.  Aberrant gata-3 expression in human pancreatic cancer.

Authors:  Antanas Gulbinas; Pascal O Berberat; Zilvinas Dambrauskas; Thomas Giese; Nathalia Giese; Frank Autschbach; Joerg Kleeff; Stefan Meuer; Markus W Büchler; Helmut Friess
Journal:  J Histochem Cytochem       Date:  2005-08-08       Impact factor: 2.479

3.  GATA binding protein 3 is down-regulated in bladder cancer yet strong expression is an independent predictor of poor prognosis in invasive tumor.

Authors:  Hiroshi Miyamoto; Koji Izumi; Jorge L Yao; Yi Li; Qi Yang; Loralee A McMahon; Nilda Gonzalez-Roibon; David G Hicks; David Tacha; George J Netto
Journal:  Hum Pathol       Date:  2012-05-18       Impact factor: 3.466

Review 4.  Transcription factor GATA3 and the human HDR syndrome.

Authors:  H Van Esch; K Devriendt
Journal:  Cell Mol Life Sci       Date:  2001-08       Impact factor: 9.261

5.  GATA Transcription Factors and Cancer.

Authors:  Rena Zheng; Gerd A Blobel
Journal:  Genes Cancer       Date:  2010-12

6.  Kidney-specific cadherin, a specific marker for the distal portion of the nephron and related renal neoplasms.

Authors:  Steven S Shen; Bhuvaneswari Krishna; Rukmini Chirala; Robert J Amato; Luan D Truong
Journal:  Mod Pathol       Date:  2005-07       Impact factor: 7.842

7.  GATA3 expression in breast carcinoma: utility in triple-negative, sarcomatoid, and metastatic carcinomas.

Authors:  Ashley Cimino-Mathews; Andrea P Subhawong; Peter B Illei; Rajni Sharma; Marc K Halushka; Russell Vang; John H Fetting; Ben Ho Park; Pedram Argani
Journal:  Hum Pathol       Date:  2013-01-31       Impact factor: 3.466

8.  GATA-3: an unexpected regulator of cell lineage determination in skin.

Authors:  Charles K Kaufman; Ping Zhou; H Amalia Pasolli; Michael Rendl; Diana Bolotin; Kim-Chew Lim; Xing Dai; Maria-Luisa Alegre; Elaine Fuchs
Journal:  Genes Dev       Date:  2003-08-15       Impact factor: 11.361

9.  Malignant fibrous histiocytoma--pleomorphic sarcoma, NOS gene expression, histology, and clinical course. A pilot study.

Authors:  Adrien Daigeler; Daigeler Adrien; Ludger Klein-Hitpass; Klein-Hitpass Ludger; Ingo Stricker; Stricker Ingo; Oliver Müller; Müller Oliver; Cornelius Kuhnen; Kuhnen Cornelius; Ansgar Michael Chromik; Chromik Ansgar Michael; Lars Steinstraesser; Steinstraesser Lars; Ole Goertz; Goertz Ole; Hans-Ulrich Steinau; Steinau Hans-Ulrich; Marcus Lehnhardt; Lehnhardt Marcus
Journal:  Langenbecks Arch Surg       Date:  2009-01-22       Impact factor: 3.445

10.  Expression of GATA-3 during lymphocyte differentiation and mouse embryogenesis.

Authors:  M Oosterwegel; J Timmerman; J Leiden; H Clevers
Journal:  Dev Immunol       Date:  1992
View more
  108 in total

Review 1.  Cervical lymph node metastases from remote primary tumor sites.

Authors:  Fernando López; Juan P Rodrigo; Carl E Silver; Missak Haigentz; Justin A Bishop; Primož Strojan; Dana M Hartl; Patrick J Bradley; William M Mendenhall; Carlos Suárez; Robert P Takes; Marc Hamoir; K Thomas Robbins; Ashok R Shaha; Jochen A Werner; Alessandra Rinaldo; Alfio Ferlito
Journal:  Head Neck       Date:  2015-12-29       Impact factor: 3.147

Review 2.  [Morphology of secondary ovarian tumors and metastases].

Authors:  L-C Horn; J Einenkel; R Handzel; A K Höhn
Journal:  Pathologe       Date:  2014-07       Impact factor: 1.011

3.  Uterine Paramesonephric Cysts in Sprague-Dawley Rats from National Toxicology Program Studies.

Authors:  Daven N Jackson-Humbles; John Curtis Seely; Ronald A Herbert; David E Malarkey; Barry S McIntyre; Paul M Foster; Darlene Dixon
Journal:  Toxicol Pathol       Date:  2018-04-29       Impact factor: 1.902

Review 4.  The Novel Marker GATA3 is Significantly More Sensitive Than Traditional Markers Mammaglobin and GCDFP15 for Identifying Breast Cancer in Surgical and Cytology Specimens of Metastatic and Matched Primary Tumors.

Authors:  Ankur R Sangoi; Bijayee Shrestha; George Yang; Ourhay Mego; Andrew H Beck
Journal:  Appl Immunohistochem Mol Morphol       Date:  2016-04

Review 5.  Immunohistochemistry in Diagnostic Parathyroid Pathology.

Authors:  Lori A Erickson; Ozgur Mete
Journal:  Endocr Pathol       Date:  2018-06       Impact factor: 3.943

6.  Gastric outlet obstruction caused by metastatic tumor of the stomach originating from primary breast cancer: A case report.

Authors:  Maho Ogawa; Tsutomu Namikawa; Toyokazu Oki; Jun Iwabu; Masaya Munekage; Hiromichi Maeda; Takahiko Tamura; Tomoaki Yatabe; Hiroyuki Kitagawa; Ken Dabanaka; Takeki Sugimoto; Michiya Kobayashi; Kazuhiro Hanazaki
Journal:  Mol Clin Oncol       Date:  2018-09-17

7.  Salivary Duct Carcinoma and Invasive Ductal Carcinoma of the Breast: A Comparative Immunohistochemical Study.

Authors:  Jalal B Jalaly; Souzan Sanati; Rebecca D Chernock; Dikson G Dibe; Samir K El-Mofty
Journal:  Head Neck Pathol       Date:  2018-01-04

8.  Letter to the editor: reply to Valeria Barresi "HOXB13 is not expressed in pleomorphic giant cell carcinoma of the bladder".

Authors:  Justine Varinot; Eva Compérat
Journal:  Virchows Arch       Date:  2018-06-22       Impact factor: 4.064

Review 9.  Immunohistochemistry in the diagnosis and classification of neuroendocrine neoplasms: what can brown do for you?

Authors:  Andrew M Bellizzi
Journal:  Hum Pathol       Date:  2019-12-17       Impact factor: 3.466

10.  Incidental finding of a small cell neuroendocrine carcinoma of the ureter.

Authors:  Obinna Obi-Njoku; Chris Bell; Prashant Ravindran Menon; Iqbal Shergill
Journal:  BMJ Case Rep       Date:  2019-08-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.